📰 Cutaneous Oncology Programs News
Cutaneous Oncology Programs News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Cutaneous Oncology Programs. Real-time updates on events, politics, business and more.
January 4, 2024
04.01.2024 - WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) - Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE therapeutics ...
September 12, 2023
WATERTOWN, Mass., Sept. 11, 2023 -- Werewolf Therapeutics, Inc. , an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate...
August 21, 2023
David F. McDermott, MD, discusses the ongoing, randomized, phase 1/2 LITESPARK-024 trial in patients with advanced renal cell carcinoma, highlighting the eligibility criteria for this clinical trial.
August 10, 2023
David F. McDermott, MD, discusses how combining HIF-2α inhibition with CDK4/6 inhibition could be an effective treatment regimen in patients with renal cell carcinoma and shared details from the LITESPARK-024 trial.
July 14, 2023
David F. McDermott, MD, discusses the randomized phase 2 LITESPARK-024 trial (NCT05468697).
August 7, 2022
Though scientists don't know why it occurs, some people experience a skin condition described as Hell's Itch following sun exposure.
August 5, 2022
Though scientists don't know why it occurs, some people experience a skin condition described as Hell's Itch following sun exposure.
August 3, 2022
Though scientists don't know why it occurs, some people experience a skin condition described as Hell's Itch following sun exposure.
August 3, 2022
Though scientists don't know why it occurs, some people experience a skin condition described as Hell's Itch following sun exposure.
August 3, 2022
Though scientists don't know why it occurs, some people experience a skin condition described as Hell's Itch following sun exposure.